RESEARCH REPORT

Geographical variation in cancer survival in England, 1991–2006: an analysis by Cancer Network

Sarah Walters,¹ Manuela Quaresma,¹ Michel P Coleman,¹ Emma Gordon,² David Forman,³ Bernard Rachet¹

¹London School of Hygiene and Tropical Medicine, London, UK
²Office for National Statistics, Newport, UK
³National Cancer Intelligence Network, London, UK

Correspondence to

Dr Sarah Walters, CRUK Cancer Survival Group, Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E, UK; sarah.walters@lshtm.ac.uk

Accepted 29 December 2010
 Published Online First
 14 February 2011

ABSTRACT

Background Reducing geographical inequalities in cancer survival in England was a key aim of the Calman–Hine Report (1995) and the NHS Cancer Plan (2000). This study assesses whether geographical inequalities changed following these policy developments by analysing the trend in 1-year relative survival in the 28 cancer networks of England.

Methods Population-based age-standardised relative survival at 1 year is estimated for 1.4 million patients diagnosed with cancer of the oesophagus, stomach, colon, lung, breast (women) or cervix in England during 1991–2006 and followed up to 2007. Regional and deprivation-specific life tables are built to adjust survival estimates for differences in background mortality. Analysis is divided into three calendar periods: 1991–5, 1996–2000 and 2001–6. Funnel plots are used to assess geographical variation in survival over time.

Results One-year relative survival improved for all cancers except cervical cancer. There was a wide geographical variation in survival with generally lower estimates in northern England. This north–south divide became less marked over time, although the overall number of cancer networks that were lower outliers compared with the England value remained stable. Breast cancer was the only cancer for which there was a marked reduction in geographical inequality in survival over time.

Conclusion Policy changes over the past two decades coincided with improved relative survival, without an increase in geographical variation. The north–south divide in relative survival became less pronounced over time but geographical inequalities persist. The reduction in geographical inequality in breast cancer survival may be followed by a similar trend for other cancers, provided government recommendations are implemented similarly.

Reducing regional inequalities in cancer survival in England was identified as a public health priority in two key policy documents relating to cancer services in England: the Calman–Hine Report of 1995 and the NHS National Cancer Plan of 2000.^{1 2} Cancer networks were founded in 2001, following these policy developments, to improve uniformity in the standard of cancer management and to ensure equitable distribution of cancer facilities and resources.²

In this paper we present estimates of 1-year age-standardised relative survival among adult patients (aged 15–99 years) diagnosed with a cancer of the oesophagus, stomach, colon, lung, breast (women)

or cervix in the 28 cancer networks (as geographically defined in 2009) in England during 1991–2006 and followed up to 31 December 2007. The temporal trend in geographical differences in survival is analysed in three calendar periods, selected to coincide with the above-mentioned developments in cancer policy: 1991–5 (pre-Calman–Hine report); 1996–2000 (post-Calman–Hine report); 2001–6 (post-NHS National Cancer Plan). These periods coincide with those used in previous published research.³

Given their role in cancer management, cancer networks are a logical unit for the analysis of regional diversity in cancer survival in England.⁴ Also, since the population of each cancer network is between 0.6 and 3.0 million, they are more suitable units of analysis of survival from individual cancers than smaller NHS geographies such as primary care organisations.^{4 5}

METHODS

Data

National cancer registration data for England were obtained from the Office for National Statistics (ONS). The National Cancer Registry at ONS collates cancer registrations submitted by regional cancer registries in England. The National Health Service Information Centre (NHS-IC) updates these records with information about death or emigration and returns this to ONS. The data were extracted from the database at ONS in October 2008. Ethical approval to conduct the study was obtained from the ONS Medical Research Service (MR1101, 20 November 2007) and from the statutory patient information advisory group (PIAG; now the Ethics and Confidentiality Committee of the National Information Governance Board) under Section 61 of the Health and Social Care Act 2001 (PIAG 1-05(c)/2007, 31 July 2007).

All adult patients (15–99 years) who were diagnosed during 1991–2006 with an invasive primary malignancy of the oesophagus, stomach, colon, lung, breast (women) or cervix were eligible for inclusion in the study. They were followed up to ascertain their vital status to 31 December 2007. Patients were excluded if the behaviour of the tumour was benign, in situ, or uncertain if benign or malignant. Patients were further excluded if their cancer was registered from a death certificate only (DCO registration) or if they died on the same day as diagnosis (zero survival). Zero survival cases were excluded because before 1995 it is not possible to distinguish between DCO registrations and zero

This paper is freely available online under the BMJ Journals unlocked scheme, see <http://jech.bmj.com/site/about/unlocked.xhtml>

Table 1 Number of patients eligible for analysis and number excluded, for adults (15–99 years) diagnosed with one of six cancers in England during 1991–2006

Malignancy	ICD-10 code*	Eligible for analysis	Exclusions			Patients included Number (%)
			DCO†	Survival‡	Other§	
Oesophagus	C15	93 279	4960	1702	626	85 991 (92.2)
Stomach	C16	127 376	9377	3334	948	113 757 (89.3)
Colon	C18	284 858	16 732	6622	4761	256 743 (90.1)
Lung	C33, C34	511 491	45 725	18 574	4979	442 213 (86.5)
Breast (women)	C50	536 526	15 674	4650	18 773	497 429 (92.7)
Cervix	C53	42 764	965	316	624	40 859 (95.5)

*International Classification of Diseases, tenth revision.

†Registration from a death certificate only (DCO).

‡Date of diagnosis equal to date of death but not flagged as a DCO registration.

§Aged 100 years or over at diagnosis, sex or vital status unknown, sex-site error, invalid dates, duplicate registration, synchronous tumours, previous cancer of the same organ or tissue since 1971, or missing geographical data.

survival cases. Patients were also excluded if their record lacked relevant geographical data. A detailed description of data cleaning and exclusions has been published.^{3 6 7} The number of patients included was approximately 90% of eligible records (table 1).

There were originally 34 cancer networks in England when they were founded in 2001.⁴ Following various mergers, there are now 28 (figure 1). We applied the current boundaries retrospectively to 1991, to enable consistent comparison over time. The number of patients included for analysis in each cancer network is shown in table 2.

Cancer Network digital boundary data, as at 1 October 2008, based on 2001 Census, Output Area Boundaries. Prepared by West Midlands Cancer Intelligence Unit (2009) on behalf of Department of Health (O.S. Licence No.: 100020290).

Figure 1 Cancer Network Boundaries, 2009.

Relative survival

We estimated relative survival 1 year after diagnosis for each cancer network by cancer, sex and calendar period. Relative survival is the ratio of the observed probability of survival and the probability of survival that would have been expected if the patients had experienced the normal background mortality in the area where they live.^{8–10}

Relative survival is therefore a method of factoring out background mortality and estimating survival from cancer without requiring information on cause of death. Background mortality was obtained from population life tables, generated from death registration data provided by ONS. Complete (single year of age) life tables for ages 0–99 years were built for men and women for three index years (1991, 2001 and 2005), using deaths for three years centred on those index years and the midyear population.¹¹ Life tables for the intervening years were created using linear interpolation. The life table for 2005 was used for 2006 and 2007.

In England, background mortality by sex and age varies by geographical region and socioeconomic status,¹² so life tables were created for each government office region and deprivation category. Patients were assigned a deprivation score based on the income domain of the indices of multiple deprivation (2004) of the lower super output area of residence at the time of diagnosis.¹³ The deprivation score was categorised according to the quintiles of indices of multiple deprivation in the 32 483 lower super output area.

Relative survival is adjusted for background mortality by age, but it will vary between regions if there are underlying differences in the age structure of cancer patient populations. To control for these differences in age structure, we produced age-standardised survival using the direct method, wherein age-specific survival is weighted by a standard population age distribution.⁶

To create age-standardised estimates it is first necessary to estimate age-specific survival. This can be difficult because of the small number of events in some age groups when disaggregating by cancer, cancer network, sex and calendar period.

Analytical strategy

To overcome the problem of too few events, we estimated age-specific excess mortality (and relative survival) using a two-step approach. Excess mortality is the observed mortality among cancer patients minus the expected mortality in the general population.

In the first step, estimates were obtained using the cohort approach, with the publicly available Stata program *strel*, which uses the maximum-likelihood approach.^{10 14} We

Table 2 Number of adult patients (15–99 years) diagnosed in England during 1991–2006 and included for analysis, by cancer and cancer network

England		Oesophagus 85 991	Stomach 113 757	Colon 256 743	Lung 442 213	Breast 497 429	Cervix 40 859
N01	Lancashire and South Cumbria	3125	4152	8466	15 584	15 368	1525
N02	Greater Manchester and Cheshire	5926	8451	15 945	33 109	29 537	3073
N03	Merseyside and Cheshire	4143	5681	11 024	23 572	20 032	2074
N06	Yorkshire	4195	6889	13 097	27 277	24 794	2698
N07	Humber and Yorkshire Coast	2102	2876	5791	11 540	10 711	1284
N08	North Trent	3271	5559	9257	19 771	17 689	1552
N11	Pan Birmingham	3201	5123	9406	16 688	18 002	1770
N12	Arden	1740	2204	5160	7851	9930	865
N20	Mount Vernon	1590	2027	5225	8458	11 846	754
N21	West London	1930	2357	5853	10 766	13 634	1056
N22	North London	1721	2398	5237	9967	12 050	865
N23	North East London	1759	2991	5211	11 701	11 213	1025
N24	South East London	1901	2693	5335	12 110	12 473	1112
N25	South West London	2122	2401	7084	10 635	14 648	998
N26	Peninsula	3651	3747	10 634	13 579	18 856	1344
N27	Dorset	1541	1778	6016	6486	9689	576
N28	Avon, Somerset and Wiltshire	3426	3726	10 530	13 370	19 735	1627
N29	Three Counties	1855	1959	6179	7127	11 426	678
N30	Thames Valley	3474	3704	10 885	16 031	23 384	1528
N31	Central South Coast	3535	4105	11 847	14 896	21 589	1481
N32	Surrey, West Sussex and Hampshire	1774	1810	5566	7875	12 032	689
N33	Sussex	2374	2210	6816	9405	13 286	750
N34	Kent and Medway	2734	2678	7042	12 568	16 202	1152
N35	Greater Midlands	3637	5344	10 742	16 809	19 769	1773
N36	North of England	5556	9544	17 623	40 194	29 984	2964
N37	Anglia	4356	5907	15 342	21 421	23 381	1773
N38	Essex	2141	2557	6251	10 136	13 863	735
N39	East Midlands	7211	8886	19 179	33 287	37 486	3138

excluded all unstable estimates, defined a priori as follows: age, sex, cancer network and period-specific estimates from strel were discarded if there were no deaths in either the first or the second half year after diagnosis. The proportion of 1-year excess mortality estimates by cancer, sex, age, period and cancer network that were discarded because of non-convergence or instability varied from 0% for breast and lung cancer to 7% for cancer of the oesophagus.

In the second step, the retained excess mortality estimates were modelled using a generalised linear model, assuming a Poisson error distribution, which enabled us to produce more reliable estimates of relative survival for all combinations of cancer, sex, age group and calendar period. Calendar period, follow-up time and five age groups (15–44, 45–54, 55–64, 65–74 and 75–99 years) were included in the model as main effects. Interactions were added between period and age, period and follow-up time, and follow-up time and age in order to deal with the non-proportionality of excess hazards over time. Backward stepwise selection was used to choose the interaction terms, while the main effects were locked into the model.

The direct method of age standardisation was then applied using the age-specific results for each cancer, sex, period, cancer network combination obtained from the generalised linear model. The standard age weights were derived from the age distribution of cancer patients diagnosed in England and Wales in 1996–9.

Funnel plots

Funnel plots are a means of presenting comparative data that avoids spurious ranking of estimates for particular population units. They permit visualisation of how much a specific value differs from the England-wide value, given the precision of the estimate.^{3 15–17} Age-standardised 1-year relative survival

estimates were plotted for each cancer network against the precision of the estimates, calculated as the inverse square of their standard errors (figure 2). The England-wide value, or ‘target’, is plotted as a solid horizontal line through the middle of the plots, together with its 95.0% and 99.8% control limits (dashed lines). The control limits around the target estimate for England were calculated as a function of the precision range of the cancer network-specific estimates. Cancer network-specific estimates (numbered in the plots) falling outside the control limits represent those cancer networks showing wider disparity from the England-wide value than could be expected due to chance alone.

RESULTS

Geographical diversity in 1-year relative survival varied by cancer (table 3). For women diagnosed in 2001–6, the range in relative survival across cancer networks varied from 15.9% (oesophageal cancer), to 3.4% (breast cancer). For men, the range varied from 14.3% (oesophagus) to 7.5% (lung). Both the range and inter-quartile range reduced over time in women for all cancers except oesophageal cancer, for which the interquartile range increased from 3.2% in 1991–5 to 5.5% in 2001–6. Among men, the range widened in both oesophageal and stomach cancer and narrowed for cancers of the lung and colon.

One-year relative survival for each cancer network is shown in funnel plots (figure 2), comparing the first and final periods (1991–5 and 2001–6, respectively).

In England, 1-year survival improved by up to 10 percentage points for all cancers analysed here over the period 1991–2006, with the exception of cervical cancer. In general, the dispersion of relative survival estimates was wide and a large proportion of cancer networks were outliers in relation to the England value. Trends in survival and the outlying cancer networks were similar

Figure 2 Funnel plots of 1-year relative survival in the cancer networks of England: by cancer, sex and period.

in men and women. For breast cancer, dispersion clearly reduced over time. There were also fewer lower outliers in 2001–6 for lung and stomach cancer in women.

To establish which cancer networks had consistently lower relative survival than the England-wide value, we summed the number of times each cancer network fell below the lower 99.8% control limit on the funnel plots across the various cancers (four in men and six in women) and the three calendar periods of diagnosis. These sets of estimates were used to measure the extent of geographical variability over time.

The number of relative survival estimates below the lower 99.8% control limit of the England-wide value across all three calendar periods is shown in figure 3. An overall figure of 12 for

men or 18 for women would indicate that relative survival was below the England lower control limit for every cancer examined, in all three periods. Cancer networks with consistently lower survival than the England-wide value are illustrated with darker shading. Figure 3 provides strong evidence of geographical clustering of poor survival from the six cancers in England. For men, poorer survival was clustered in the north, whereas cancer networks in the south and west had survival consistent with the England estimate. For women, the north–south pattern was similar, although less marked, with a larger number of outlying estimates in the south west than found for men.

Figure 4 shows the number of survival estimates below the 99.8% control limit within each calendar period (results shown

Figure 2 Continued.

for 1991–5 and 2001–6). A total of four in men and six in women would indicate that the cancer network was an outlier for all cancers examined. Although the number of cancer networks that are lower outliers has remained relatively stable over time, the north–south divide was less pronounced for patients diagnosed in 2001–6 than for patients diagnosed in 1991–5.

Overall, the proportion of cancer and cancer network combinations that were lower outliers compared with the England value was relatively stable across the three calendar periods for women, with the proportion at 24%, 26% and 24% in each of the three periods. By contrast, for men, 21% and 22% of cancer

network-specific survival estimates were below the lower control limit in 1991–5 and 1996–2000, respectively, but this figure rose to 28% in the period 2001–6. The percentage of cancer network-specific survival estimates that were outliers above the upper control limit decreased over time. The percentage fell from 40% to 27% for men and from 40% to 29% for women between the first and last calendar periods of diagnosis. Much of the reduction occurred in the second period (1995–2000).

To consider the potential effect of variable data quality on differences in survival by cancer network, the proportion of DCO registrations was compared between cancer networks (by sex,

Figure 2 Continued.

calendar period and cancer) and the correlation with relative survival was ascertained (table 4). The variation in the proportion of all exclusions combined depends almost solely on the proportion of DCO registrations, other exclusion categories being rare or, for multiple tumours for a given cancer site, very stable between cancer networks. DCO registrations in conjunction with zero survival represent 80.7% of the exclusions in this study (table 1). Table 4 shows that the greatest variability in the proportion of DCO registrations occurred in 1991–5, and this proportion declined over time. There was indeed some correlation between the proportion of DCO registrations and relative survival in this earliest period, but no evidence of continuing correlation after 1995 (except for oesophageal cancer, for which there was some correlation in 1996–2000).

DISCUSSION

In England, 1-year relative survival improved dramatically for all cancers analysed, with the exception of cervical cancer, between

1991 and 2006. The lack of improvement in cervical cancer survival has been found in previous studies and may be attributable to stage migration following the introduction of effective screening.^{18 19} Since 1998, cervical screening has reached at least 85% of eligible women in England. Near-universal screening means that many more cancers are detected at an in situ stage, and are removed before they become invasive. This has led to a dramatic decline in the incidence of invasive cancers.^{20–22} There is mounting evidence from other countries with near-universal screening programmes that the invasive cancers that are now identified tend to occur in women who have not attended screening, or to be particularly aggressive cancers with poor prognosis.^{22–26} Given the improvement in multidisciplinary team working and chemotherapeutic advances for cervical cancer since the 1990s it is more likely that screening rather than treatment explains the plateau in survival for this cancer.¹⁹

The results of this study show clear geographical inequality in survival. Cancer networks that had consistently low outlying

Table 3 One-year relative survival (%) in England, and range and IQR in 1-year relative survival across cancer networks, by cancer, calendar period of diagnosis and sex

Cancer	Sex	England (%)			Overall range			IQR		
		1991–5	1996–2000	2001–6	1991–5	1996–2000	2001–6	1991–5	1996–2000	2001–6
Oesophagus	Men	26.5	30.0	36.7	14.1	17.2	14.3	3.9	5.9	5.5
	Women	25.6	27.2	32.1	13.3	15.1	15.9	3.2	4.5	5.5
Stomach	Men	29.5	33.9	38.8	11.4	17.1	13.9	3.8	4.8	5.1
	Women	29.1	32.4	35.6	18.6	12.5	13.3	8.8	4.7	4.8
Colon	Men	65.2	68.7	70.7	15.3	11.2	12.1	4.6	3.5	3.6
	Women	62.7	66.3	67.8	13.9	10.8	10.9	6.1	3.6	3.7
Lung	Men	21.3	24.0	26.4	9.4	7.4	7.5	4.6	2.6	2.4
	Women	21.6	25.2	28.9	11.3	10.4	11.1	4.5	3.6	3.0
Breast	Women	91.5	93.5	94.9	5.3	3.8	3.4	2.9	1.2	0.8
Cervix	Women	82.8	82.7	82.4	10.5	9.3	8.4	2.4	3.3	3.2

Figure 3 The number of cancers (out of four in men and six in women) for which relative survival fell below the lower 99.8% control limit of the England value, totalled over three calendar periods, by sex and cancer network.

survival estimates compared with the England estimates were clustered across northern England and the East Midlands, while results for southern and western cancer networks were more consistently comparable with, or above, the England estimates. This broadly confirms the findings of previous studies that have pointed to the north–south divide in cancer survival in England.^{5 6 27 28}

The largest increase in the proportion of cancer networks that were low outliers occurred in the period 2001–6, following the NHS National Cancer Plan. This increase was observed in men only. Three of the four cancers in men were poor prognosis cancers, compared with three of the six in women, and it is possible that this played a role in the sex difference observed

Figure 4 The number of cancers (out of four in men and six in women) for which relative survival fell below the lower 99.8% control limit of the England value, by calendar period (showing 1991–5 and 2001–6), sex and cancer network.

here. To explain why the proportion of low outliers increased for men but not women, it is also worth noting that women had a higher degree of variation at baseline for at least two cancers: the IQR for cancers of the oesophagus and colon was considerably higher in women (table 3).

The lack of a significant reduction in geographical inequalities in cancer survival following the NHS National Cancer Plan echoes previous research showing there has been little or no reduction in the deprivation gap in short-term survival by socioeconomic status in England in this period.²⁹

Given the large rise in overall survival, however, it is notable that the geographical inequalities have not widened more significantly, as shown by the rather stable proportion of cancer networks that were low survival outliers over time. Furthermore, even though the number of lower outliers remained stable over time, the distribution of these outliers has shifted, leading to a less-pronounced north–south divide in survival.

Although regional disparities in survival from most of these cancers did not fall over time, breast cancer is the exception, with a distinct convergence of the cancer network-specific survival estimates around the England value in the later period. The reduced variation can partly be explained by the fact that 1-year survival from breast cancer in 2001–6 is reaching the ceiling of 100%. Even accounting for this, it is clear that variation reduced, as can be seen by the relatively small number of outliers outside the (very narrow) control limits on the funnel plots in the final period. This is an important finding given that the improving outcomes guidance (IOG) issued in the mid-1990s was implemented earliest for this cancer. Multidisciplinary team working was universally established for breast cancer by the

Table 4 Range of percentage of eligible patients that were DCO registrations across cancer networks (minimum and maximum presented), Spearman rank correlation with 1-year relative survival, by cancer, calendar period of diagnosis and sex

Cancer	Sex	1991–5				1996–2000				2001–6			
		Minimum	Maximum	r	p value	Minimum	Maximum	r	p value	Minimum	Maximum	r	p value
Oesophagus	Men	1.3	26.5	0.298	0.124	0.0	12.9	0.402	0.034	0.0	7.0	0.210	0.283
	Women	1.4	24.8	0.143	0.468	0.2	16.6	0.224	0.251	0.0	8.1	0.228	0.244
Stomach	Men	3.3	30.4	0.568	0.002	0.0	18.5	0.226	0.247	0.0	9.4	0.066	0.740
	Women	3.5	37.4	0.585	0.001	0.2	22.4	0.067	0.734	0.0	13.4	−0.078	0.694
Colon	Men	1.3	23.3	0.525	0.004	0.2	14.4	0.308	0.111	0.0	7.5	0.179	0.362
	Women	2.9	28.4	0.545	0.003	0.2	16.3	0.438	0.020	0.0	8.7	0.246	0.207
Lung	Men	4.4	35.9	0.656	<0.001	0.2	19.5	0.324	0.093	0.0	15.1	0.068	0.731
	Women	3.5	36.1	0.742	<0.001	0.4	20.8	0.232	0.235	0.0	15.9	0.278	0.152
Breast	Women	0.6	13.1	0.363	0.058	0.1	7.2	0.216	0.269	0.0	4.0	−0.077	0.696
Cervix	Women	0.6	13.2	0.152	0.439	0.0	7.0	0.041	0.836	0.0	4.2	−0.037	0.853

DCO, death certificate only.

time it was assessed by the Audit Commission in 2001. At that time, implementation of the IOG for lung, bowel and the gynaecological cancers was uneven across the country.³⁰

If this reasoning is correct, it may be hypothesised that the reduction in geographical inequalities for breast cancer may soon be followed by a similar convergence in regional survival for other cancers, provided the guidance issued in the manual for cancer services³¹ (which has now replaced the IOG) is implemented with the same dedication and with equivalent resources as for breast cancer. We may even predict that regional disparities in survival from bowel cancer will similarly decline in the near future, since the National Cancer Peer Review of 2004–7 established that multidisciplinary teams in this sector had caught up with the breast cancer standard.³²

A further issue to consider is the impact of screening on regional variation in survival through earlier diagnosis. Three of the six cancers included in this analysis were the subject of screening programmes. National programmes of cervical and breast cancer screening were effective throughout this study period, and two rounds of the colorectal screening pilot were conducted in 2000 and 2003–5 in some primary care trusts (PCT) in the Arden cancer network (N12).

Given that the proportion of eligible women attending screening for cervical cancer has remained stable since the late 1990s at over 80% in nearly 90% of health authorities,²¹ it is unlikely that the screening programme was responsible for the reduction in geographical inequalities in survival during 1991–2006.

Breast cancer screening expanded during the period of study in terms of the number of eligible women reached and the definition of eligible women. By 2006, coverage was over 70% of eligible women in 90% of PCTs and screening was contributing to the reduction of breast cancer mortality.^{33–34} However, less than one third of invasive breast cancers are screen detected.³⁵ It is therefore unlikely that expansion of the screening programme played an important role in rising regional equality in breast cancer survival.

The colorectal screening pilot was rolled out in several PCT in the Coventry and Warwickshire area in 2000 and 2005–7. These PCT became part of the Arden cancer network when it was formed in 2002.³⁶ Survival from cancer of the colon did improve very slightly in Arden relative to other cancer networks between 1996–2000 and 2001–6, but so did survival for patients with lung cancer and in women with oesophageal and cervical cancer. It is too early to say whether the launch of the national bowel cancer screening programme in 2007 will reduce geographical inequalities in survival.³⁷

It is unlikely that variation in the quality of registration data has contributed to the regional inequalities identified in cancer survival, at least since the mid-1990s. Registration quality in England is determined by cancer registries (of which there are eight) rather than cancer networks. The annual reports of the United Kingdom Association of Cancer Registries show that quality is relatively homogenous between the registries today (with the exception of bladder cancer, see below).³⁸ The proportion of eligible patients excluded from analysis through the quality control conducted for this analysis was largely driven by the number of DCO registrations and patients with zero survival (making up 80.7% of all exclusions). We showed in table 4 that this proportion was indeed correlated with survival in 1991–5, but not in the later calendar periods, and that regional diversity in the proportion of DCO has decreased.

The cancer sites included in this study were those incorporated for survival analysis in the annual compendium of clinical and health indicators for public health monitoring in England.³⁹ Bladder and prostate cancer are also included in those indicators but were excluded here. Results for bladder cancer were excluded because wide changes in pathological coding, and diversity between cancer

What is already known on this subject

There is a north-south divide in cancer survival in England, with lower survival in the north. Policy changes under the Labour Government, including the NHS Cancer Plan (2000), aimed to reduce geographic inequality in survival. It is necessary to assess whether these policy changes have reduced geographic inequality in survival in England. This study uses the most suitable unit for analysis: cancer networks, which were formed to oversee the process.

What this study adds

There has been a lessening of the north-south divide in cancer survival but the overall level of geographic inequality has remained stable despite policy change. Breast cancer is the exception, showing a reduction in geographic variation in survival. If guidance is implemented with the same consistency for other cancers, geographic inequality in cancer survival may similarly decline.

registries in the implementation of those changes, have led to non-interpretable trends in survival. Age-standardised survival from prostate cancer proved to be very difficult to estimate because of small numbers of deaths in some age groups at the cancer network level, so results were not reported.

We acknowledge that presenting data grouped by calendar period disguises fluctuations in trends and may not accurately portray the timing of change; however, the small sample sizes in the analysis by cancer network precluded the estimation of annual relative survival. Further methodological developments are in progress to enable age standardisation for small populations, in order that survival estimates can be produced for sparse data.⁵

Acknowledgements The authors would like to thank the GIS team at the West Midlands Cancer Intelligence Unit for supplying the cancer network digital boundary information and the staff of the English cancer registries for collecting the data on which this analysis is based.

Funding This study was funded by the National Cancer Intelligence Network, National Cancer Research Institute (NCRI), 18th Floor, Portland House, Bressenden Place, London SW1E 5RS.

Competing interests None.

Ethics approval This study was conducted with the approval of the ONS Medical Research Service (MR1101, 20 November 2007). Patient Information Advisory Group (PIAG; now the Ethics and Confidentiality Committee of the National Information Governance Board) under Section 61 of the Health and Social Care Act 2001 (PIAG 1-05(c)/2007, 31 July 2007).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. **Expert Advisory Group on Cancer.** *A policy framework for commissioning cancer services.* London: Department of Health, 1995.
2. **Department of Health.** *The NHS Cancer Plan.* London: Department of Health, 2000.
3. **Rachet B, Maringe C, Nur U, et al.** Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. *Lancet Oncol* 2009;**10**:351–69.
4. **Ellis L, Rachet B, Coleman MP.** Cancer survival indicators by cancer network: a methodological perspective. *Health Stat Quart* 2007;**36**:41. Winter.
5. **Quaresma M, Walters S, Gordon E, et al.** A cancer survival index for Primary Care Trusts. ONS 2010. <http://www.statistics.gov.uk/statbase/Product.asp?vlnk=15388> (accessed 17 Dec 2010).
6. **Coleman MP, Babb P, Damiacki P, et al.** *Cancer survival trends in England and Wales 1971–1995: deprivation and NHS region. Studies on medical and population subjects no. 61.* London: The Stationery Office, 1999.
7. **Walters S, Rachet B, Westlake S, et al.** *Cancer survival, England, patients diagnosed 2001–2006 and followed up to 2007: one-year and five-year survival for 21 common cancers, by sex and age.* ONS, 2009. http://www.statistics.gov.uk/downloads/theme_health/cancer-survival-Eng-2001-2006.pdf (accessed 17 Dec 2010).
8. **Berkson J, Gage RP.** Calculation of survival rates for cancer. *Proc Staff Meet Mayo Clinic* 1950;**25**:270–86.
9. **Estève J, Benhamou E, Raymond L.** *Statistical methods in cancer research, volume IV. Descriptive epidemiology. (IARC Scientific Publications No. 128).* Lyon: International Agency for Research on Cancer, 1994.
10. **Estève J, Benhamou E, Croasdale M, et al.** Relative survival and the estimation of net survival: elements for further discussion. *Stat Med* 1990;**9**:529–38.
11. **Cancer Research UK Cancer Survival Group.** *Life tables for England and Wales by sex, calendar period, region and deprivation.* 2004. <http://www.lshtm.ac.uk/ncdeu/cancersurvival/tools.htm> (accessed 17 Dec 2010).
12. **Woods LM, Rachet B, Riga M, et al.** Geographical variation in life expectancy at birth in England and Wales is largely explained by deprivation. *J Epidemiol Community Health* 2005;**59**:115–20.
13. **Neighbourhood Renewal Unit.** *The English indices of deprivation 2004 (revised).* London: Office for the Deputy Prime Minister, 2004.
14. **Cancer Research UK Cancer Survival Group.** *Strel computer program version 1.2 for cancer survival analysis.* London School of Hygiene and Tropical Medicine, 2006. www.lshtm.ac.uk/ncdeu/cancersurvival/tools.htm (accessed 17 Dec 2010).
15. **Coleman MP, Quaresma M, Berrino F, et al.** Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol* 2008;**9**:730–56.
16. **Ito Y, Ioka A, Tsukuma H, et al.** Regional differences in population-based cancer survival between six prefectures in Japan: application of relative survival models with funnel plots. *Cancer Sci* 2009;**100**:1306–11.
17. **Spiegelhalter DJ.** Funnel plots for comparing institutional performance. *Stat Med* 2005;**24**:1185–202.
18. **Quinn MJ, Cooper N, Rachet B, et al.** Survival from cancer of the uterine cervix in England and Wales up to 2001. *Br J Cancer* 2008;**99**(Suppl 1):59–62.
19. **Kitchener HC.** Clinical commentary—survival from cancer of the ovary in England and Wales up to 2001. *Br J Cancer* 2008;**99**(Suppl 1):73–4.
20. **Cervical Screening Programme, England: 1997–98.** National Health Service, 1999. <http://www.cancerscreening.nhs.uk/cervical/cervical-statistics-bulletin-1997-98.pdf> (accessed 17 Dec 2010).
21. **NHS Cervical Screening Programme.** *Cervical Screening Programme Review, 1999.* <http://www.cancerscreening.nhs.uk/cervical/publications/1999cervical.pdf> (accessed 17 Dec 2010).
22. **Stockton D, Cooper P, Lonsdale RN.** Changing incidence of invasive adenocarcinoma of the uterine cervix in East Anglia. *J Med Screen* 1997;**4**:40–3.
23. **Smith HO, Tiffany MF, Qualls CR, et al.** The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. *Gynecol Oncol* 2000;**78**:97–105.
24. **Sherman ME, Wang SS, Carreon J, et al.** Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. *Cancer* 2005;**103**:1258–64.
25. **Vinh-Hung V, Bourgain C, Vlastos G, et al.** Prognostic value of histopathology and trends in cervical cancer: a SEER population study. *BMC Cancer* 2007;**7**:164.
26. **Mathew A, George PS.** Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix — worldwide. *Asian Pac J Cancer Prev* 2009;**10**:645–50.
27. **Mullee M, De Stavola BL, Romanengo M, et al.** Geographical variation in breast cancer survival rates for women diagnosed in England between 1992 and 1994. *Br J Cancer* 2004;**90**:2153–6.
28. **Yuen J, Haybittle J, Machin D.** Geographical variation in the standardised years of potential life lost ration (SYPLR) in women dying from malignancies of the breast in England and Wales. *Br J Cancer* 1997;**75**:1069–74.
29. **Rachet B, Ellis L, Maringe C, et al.** Socioeconomic inequalities in cancer survival in England after the NHS Cancer Plan. *Br J Cancer* 2010;**103**:446–53.
30. **National Audit Office.** *Tackling cancer in England: saving more lives. HC 364 Session 2003–2004, 1–64. 19-3-2004.* London: The Stationery Office, 2004.
31. **Department of Health.** *Manual for Cancer Services.* London: Department of Health, 2004.
32. **National Cancer Action Team.** *National Cancer Peer Review Programme 2004–2007 National Report: an overview of the findings from the second round of peer reviews of cancer services in England.* London: Department of Health, 2010.
33. **Blanks RG, Moss SM, McGahan CE, et al.** Effect of NHS Breast Screening Programme on mortality from breast cancer in England and Wales, 1990–8: comparison of observed with predicted mortality. *BMJ* 2000;**321**:665–9.
34. **Breast Screening Programme, England, 2005–06.** NHS Information Centre, 2007. <http://www.cancerscreening.nhs.uk/breastscreen/breast-statistics-bulletin-2005-06.pdf> (accessed 17 Dec 2010).
35. **Cheung S, Greenway N, Lagord C, et al.** *All Breast Cancer Report: a UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006: NHS Breast Screening Programme, 2009.* <http://www.wmpho.org.uk/wmciu/documents/All%20Breast%20Cancer%20Report%20pp.pdf> (accessed 17 Dec 2010).
36. **Alexander F, Weller D.** *Evaluation of the UK Colorectal Cancer Screening Pilot. The UK CRC Screening Pilot Evaluation Team, 2003.* <http://www.cancerscreening.nhs.uk/bowel/finalreport.pdf> (accessed 17 Dec 2010).
37. **Department of Health.** *Cancer reform strategy.* London, Department of Health, 2007:1–17.
38. **UK Association of Cancer Registries (UKACR).** *Data quality.* <http://www.ukacr.org/content/data-quality>. (accessed 5 Nov 2010).
39. **NHS Clinical and Health Outcomes Knowledge Base: NCHOD, 2010.** <http://www.nchod.nhs.uk> (accessed 10 Aug 2010).